FDA denies Lexicon Pharmaceuticals' (LXRX) appeal of the CRL it received in March for the Marketing Application of type 1 diabetes med sotagliflozin

Source Link:

http://www.lexpharma.com/media-center/news/730-lexicon-pharmaceuticals-receives-formal-dispute-resolution-request-decision-from-fda-s-office-of-new-drugs-for-sotagliflozin-in-type-1-diabetes